Stay updated with breaking news from Source Cstone Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator Professor Yi-Long Wu was...
The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose...
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients - read this article along with other careers information, tips and advice on BioSpace
Press release content from PR Newswire. The AP news staff was not involved in its creation.
/PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China...